Faculty Opinions recommendation of Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
The HIVEC-II study is a prospective multicenter, randomized, open label, phase II study that took place in three hospitals in the United Kingdom and evaluated the benefit of applying chemohyperthermia (CHT) as an adjuvant therapy after transurethral resection of bladder tumors (TURB). The treatment arm of the study received Mitomycine C (MMC) together with hyperthermia delivered by the COMBAT system, which recirculates MMC heated to 43ºC. The control arm received only MMC. The primary endpoint was 24-month disease-free survival as determined via cystoscopy and urinary cytology. Analysis was by intention to treat. The study showed a lower disease free survival rate on the CHT group at a 24-month follow-up, suggesting the conclusion that there it no oncological benefit in applying CHT with MMC. Some possible limitations of the study might be that applying MMC in the immediate postoperative period or maintaining the treatment with MMC for 1 year could alter the results. We want to highlight the importance of publishing negative studies like this one to avoid publication bias. Trial registration details: ISRCTN 23639415.